Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.

Spurgeon SE, Sharma K, Claxton DF, Ehmann C, Pu J, Shimko S, Stewart A, Subbiah N, Palmbach G, LeBlanc F, Latour E, Chen Y, Mori M, Hasanali Z, Epner EM.

Br J Haematol. 2019 Jun 9. doi: 10.1111/bjh.16008. [Epub ahead of print]

PMID:
31177537
2.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

3.

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.

Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM.

Oncotarget. 2018 May 15;9(37):24576-24589. doi: 10.18632/oncotarget.25191. eCollection 2018 May 15.

4.

Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.

Gordon MJ, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D, Danilov AV.

Cancer. 2018 Aug 1;124(15):3192-3200. doi: 10.1002/cncr.31554. Epub 2018 May 24.

5.

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.

Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, Loriaux MM, Spurgeon SEF, Danilova OV, Danilov AV.

Haematologica. 2017 Nov;102(11):1890-1900. doi: 10.3324/haematol.2017.170571. Epub 2017 Aug 24.

6.

Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.

Scott EC, Maziarz RT, Spurgeon SE, Medvedova E, Gajewski J, Reasor-Heard S, Park B, Kratz A, Thomas GV, Loriaux M, Cascio M, Podolak J, Gordon M, Botelho J, Stadtmauer E, Amaravadi R, Vogl DT.

Haematologica. 2017 Jul;102(7):e261-e265. doi: 10.3324/haematol.2016.162321. Epub 2017 Apr 6. No abstract available.

7.

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR.

J Natl Cancer Inst. 2016 Dec 31;109(1). doi: 10.1093/jnci/djw263. Print 2017 Jan. Review.

8.

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, Mayer LD, Tyner JW.

Leuk Res. 2017 Feb;53:39-49. doi: 10.1016/j.leukres.2016.12.002. Epub 2016 Dec 12.

PMID:
28013106
9.

Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.

Raess PW, Cascio MJ, Fan G, Press R, Druker BJ, Brewer D, Spurgeon SE.

Am J Hematol. 2017 Jan;92(1):E6-E8. doi: 10.1002/ajh.24586. Epub 2016 Nov 18. No abstract available.

10.

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH.

Sci Transl Med. 2016 Aug 31;8(354):354ra114. doi: 10.1126/scitranslmed.aaf5309.

PMID:
27582059
11.

Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.

Gordon MJ, Raess PW, Young K, Spurgeon SEF, Danilov AV.

Br J Haematol. 2017 Nov;179(3):501-503. doi: 10.1111/bjh.14224. Epub 2016 Jul 8. No abstract available.

PMID:
27391978
12.

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, Liem AK, Mclntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW.

Blood. 2016 May 19;127(20):2411-5. doi: 10.1182/blood-2015-12-683516. Epub 2016 Mar 11.

13.

Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.

Paiva C, Godbersen JC, Soderquist RS, Rowland T, Kilmarx S, Spurgeon SE, Brown JR, Srinivasa SP, Danilov AV.

PLoS One. 2015 Nov 25;10(11):e0143685. doi: 10.1371/journal.pone.0143685. eCollection 2015.

14.

Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.

Stephens DM, Spurgeon SE.

Ther Adv Hematol. 2015 Oct;6(5):242-52. doi: 10.1177/2040620715592569. Review.

15.

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.

Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW.

Oncotarget. 2015 Aug 7;6(22):18921-32.

16.

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S.

Blood. 2015 Aug 6;126(6):739-45. doi: 10.1182/blood-2015-03-635326. Epub 2015 Jun 9.

17.

Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome.

Braun TP, Maxson JE, Agarwal A, Dunlap J, Spurgeon SE, Traer E.

Leuk Res Rep. 2014 Dec 25;4(1):8-11. doi: 10.1016/j.lrr.2014.12.003. eCollection 2015.

18.

Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event.

Geller MD, Pei Y, Spurgeon SE, Durum C, Leeborg NJ.

Cancer Genet. 2014 Jul-Aug;207(7-8):340-3. doi: 10.1016/j.cancergen.2014.09.004. Epub 2014 Sep 19. Review.

PMID:
25441688
19.

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.

Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK.

Br J Haematol. 2015 Jan;168(1):38-45. doi: 10.1111/bjh.13099. Epub 2014 Aug 22.

PMID:
25146490
20.

Aberrations of MYC are a common event in B-cell prolymphocytic leukemia.

Flatley E, Chen AI, Zhao X, Jaffe ES, Dunlap JB, Pittaluga S, Abdullah S, Olson SB, Spurgeon SE, Fan G.

Am J Clin Pathol. 2014 Sep;142(3):347-54. doi: 10.1309/AJCPUBHM8U7ZFLOB.

PMID:
25125625
21.

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE.

Oncotarget. 2014 Feb 28;5(4):908-15.

22.

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND.

Blood. 2014 May 29;123(22):3398-405. doi: 10.1182/blood-2013-11-537555. Epub 2014 Mar 10.

23.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR.

Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.

24.

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE.

Blood. 2014 May 29;123(22):3406-13. doi: 10.1182/blood-2013-11-538546. Epub 2014 Mar 10.

25.

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.

Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR.

Blood. 2014 Feb 27;123(9):1302-8. doi: 10.1182/blood-2013-07-512137. Epub 2013 Dec 31.

26.

Concurrent presentation of hodgkin lymphoma and multiple myeloma.

Chandran R, Simon M, Spurgeon SE.

Case Rep Hematol. 2013;2013:398769. doi: 10.1155/2013/398769. Epub 2013 Aug 20.

27.

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.

Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE.

Leukemia. 2013 Oct;27(10):2094-6. doi: 10.1038/leu.2013.228. Epub 2013 Jul 31. No abstract available.

PMID:
23900138
28.

Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors.

Chandran R, Gardiner SK, Smith SD, Spurgeon SE.

Br J Haematol. 2013 Nov;163(3):407-9. doi: 10.1111/bjh.12490. Epub 2013 Jul 24. No abstract available.

PMID:
23889044
29.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA.

N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.

30.

The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM.

J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. doi: 10.1124/jpet.112.200832. Epub 2012 Dec 7.

31.

Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM.

Cancer Res. 2013 Jan 1;73(1):285-96. doi: 10.1158/0008-5472.CAN-12-1906. Epub 2012 Oct 18.

32.

Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007.

Chandran R, Gardiner SK, Simon M, Spurgeon SE.

Leuk Lymphoma. 2012 Aug;53(8):1488-93. doi: 10.3109/10428194.2012.656628. Epub 2012 Feb 13.

PMID:
22242824
33.

Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.

Spurgeon SE, Pindyck T, Okada C, Chen Y, Chen Z, Mater E, Abbi K, Epner EM.

Leuk Lymphoma. 2011 Aug;52(8):1488-94. doi: 10.3109/10428194.2011.575489. Epub 2011 May 31.

PMID:
21623691
34.

Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.

Spurgeon SE, Mongoue-Tchokote S, Collins L, Priest R, Hsieh YC, Peters LM, Beer TM, Mori M, Garzotto M.

Urology. 2007 May;69(5):931-5.

PMID:
17482937
35.

Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy.

Spurgeon SE, Hsieh YC, Rivadinera A, Beer TM, Mori M, Garzotto M.

J Urol. 2006 Mar;175(3 Pt 1):918-22.

PMID:
16469580

Supplemental Content

Loading ...
Support Center